BRPI0819188A2 - Uso de melanocortinas para tratar sensibilidade à insulina. - Google Patents

Uso de melanocortinas para tratar sensibilidade à insulina.

Info

Publication number
BRPI0819188A2
BRPI0819188A2 BRPI0819188-3A BRPI0819188A BRPI0819188A2 BR PI0819188 A2 BRPI0819188 A2 BR PI0819188A2 BR PI0819188 A BRPI0819188 A BR PI0819188A BR PI0819188 A2 BRPI0819188 A2 BR PI0819188A2
Authority
BR
Brazil
Prior art keywords
melanocortins
insulin sensitivity
treat insulin
treat
sensitivity
Prior art date
Application number
BRPI0819188-3A
Other languages
English (en)
Inventor
Heather A Halem
Michael Dewitt Culler
Andrew A Butler
Original Assignee
Ipsen Pharma Sas
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas, Univ Louisiana State filed Critical Ipsen Pharma Sas
Publication of BRPI0819188A2 publication Critical patent/BRPI0819188A2/pt
Publication of BRPI0819188B1 publication Critical patent/BRPI0819188B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
BRPI0819188-3A 2007-11-05 2008-11-05 Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina BRPI0819188B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05
US61/001,933 2007-11-05
PCT/US2008/012490 WO2009061411A2 (en) 2007-11-05 2008-11-05 Use melanocortins to treat insulin sensitivity

Publications (2)

Publication Number Publication Date
BRPI0819188A2 true BRPI0819188A2 (pt) 2015-09-01
BRPI0819188B1 BRPI0819188B1 (pt) 2021-06-22

Family

ID=40626385

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819188-3A BRPI0819188B1 (pt) 2007-11-05 2008-11-05 Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina

Country Status (21)

Country Link
US (6) US9155777B2 (pt)
EP (2) EP2979703B1 (pt)
JP (3) JP2011502987A (pt)
KR (3) KR101662044B1 (pt)
CN (2) CN101980717A (pt)
AR (1) AR069461A1 (pt)
AU (1) AU2008325194B2 (pt)
BR (1) BRPI0819188B1 (pt)
CA (2) CA2704651C (pt)
DK (1) DK2214693T3 (pt)
ES (2) ES2690556T3 (pt)
HK (3) HK1146242A1 (pt)
HU (1) HUE026842T2 (pt)
IL (2) IL205554A (pt)
NZ (1) NZ585131A (pt)
PL (1) PL2214693T3 (pt)
PT (2) PT2214693E (pt)
RU (1) RU2453328C2 (pt)
TR (1) TR201815292T4 (pt)
TW (1) TWI374030B (pt)
WO (1) WO2009061411A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5250026B2 (ja) * 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
EP2979703B1 (en) * 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
RU2012108110A (ru) * 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии
EP2473518B1 (en) * 2009-08-31 2017-02-22 Tensive Controls, Inc. Stabilized melanocortin ligands
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
EP2504352B1 (en) 2009-11-23 2018-11-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
CN102712674A (zh) 2009-11-23 2012-10-03 帕拉丁科技公司 黑皮质素-1受体-特异性的线性肽
UA114088C2 (xx) * 2011-06-14 2017-04-25 Лікарська композиція з пролонгованим вивільненням для ін'єкцій
EP3539551B1 (en) 2011-12-29 2021-10-06 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
CN105492456A (zh) 2013-03-15 2016-04-13 节奏制药公司 肽组合物
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
WO2016130966A1 (en) * 2015-02-13 2016-08-18 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN ANALOGUES (1-7) AND ASSOCIATED METHODS
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US11763106B2 (en) 2018-06-05 2023-09-19 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
WO2002023184A1 (en) 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
JP2005531583A (ja) * 2002-05-23 2005-10-20 カイロン コーポレイション 置換キナゾリノン化合物
DE60313844T2 (de) 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
DE602004028228D1 (de) 2003-03-26 2010-09-02 Merck Sharp & Dohme Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
EA200600055A1 (ru) * 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
CA2557739A1 (en) * 2004-03-29 2005-11-03 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
US20080200376A1 (en) * 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
US8349797B2 (en) * 2005-07-08 2013-01-08 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
PL3354273T3 (pl) * 2005-07-08 2021-10-11 Ipsen Pharma Ligandy receptora melanokortyny
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
JP5250026B2 (ja) * 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2979703B1 (en) * 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
RU2012108110A (ru) 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии

Also Published As

Publication number Publication date
CA2952095A1 (en) 2009-05-14
CA2952095C (en) 2020-02-18
BRPI0819188B1 (pt) 2021-06-22
US9155777B2 (en) 2015-10-13
HK1146242A1 (en) 2011-05-27
JP2013144690A (ja) 2013-07-25
US20160354429A1 (en) 2016-12-08
IL249998A0 (en) 2017-03-30
EP2214693B1 (en) 2015-09-09
CN101980717A (zh) 2011-02-23
TR201815292T4 (tr) 2018-11-21
TWI374030B (en) 2012-10-11
US20190111105A1 (en) 2019-04-18
US20220339239A1 (en) 2022-10-27
WO2009061411A3 (en) 2010-04-15
KR101290623B1 (ko) 2013-08-07
ES2690556T3 (es) 2018-11-21
RU2010122897A (ru) 2011-12-20
AU2008325194A1 (en) 2009-05-14
PL2214693T3 (pl) 2016-03-31
WO2009061411A2 (en) 2009-05-14
CA2704651A1 (en) 2009-05-14
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
ES2555522T3 (es) 2016-01-04
IL249998B (en) 2018-07-31
EP2979703B1 (en) 2018-07-18
KR20130065725A (ko) 2013-06-19
EP2214693A2 (en) 2010-08-11
JP5964767B2 (ja) 2016-08-03
US9827286B2 (en) 2017-11-28
HK1221147A1 (zh) 2017-05-26
RU2453328C2 (ru) 2012-06-20
KR20150013339A (ko) 2015-02-04
US20100311647A1 (en) 2010-12-09
JP2011502987A (ja) 2011-01-27
HK1184692A1 (zh) 2014-01-30
AU2008325194B2 (en) 2012-04-19
EP2214693A4 (en) 2012-04-11
CN103316345A (zh) 2013-09-25
DK2214693T3 (en) 2015-11-30
IL205554A (en) 2017-01-31
EP2979703A1 (en) 2016-02-03
US20150366934A1 (en) 2015-12-24
US9439943B2 (en) 2016-09-13
IL205554A0 (en) 2010-12-30
PT2979703T (pt) 2018-10-31
CA2704651C (en) 2017-03-07
PT2214693E (pt) 2015-12-07
JP2015131827A (ja) 2015-07-23
NZ585131A (en) 2012-10-26
US20180303899A1 (en) 2018-10-25
TW200932258A (en) 2009-08-01
AR069461A1 (es) 2010-01-27
CN103316345B (zh) 2016-05-18
HUE026842T2 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
BRPI0819188A2 (pt) Uso de melanocortinas para tratar sensibilidade à insulina.
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0821668A2 (pt) Uso
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
BRPI0807487A2 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0813449A2 (pt) Formas de dosagem sólida ou semissólida de liberação modificada.
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0717411A2 (pt) Uso de inibidores de iap
BRPI0915134A2 (pt) composto, e, uso de um composto
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0812991A2 (pt) Utilização de combustível melhorado
BRPI0919216A2 (pt) poliuretano, e, uso de um poliuretano
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
BRPI0907053A2 (pt) Poliisobutenoamina, composição combustível, e, uso de poliisobutenoaminas
BRPI0917360A2 (pt) uso de d-ribose para indivíduos cansados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.